Literature DB >> 1860636

Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat.

J F Jeannin1, N Onier, P Lagadec, N von Jeney, P Stütz, E Liehl.   

Abstract

Colon carcinoma is one of the most frequent causes of cancer death in industrialized countries. The patients generally die of the metastases. In a colon cancer rat model, the authors have shown that lipopolysaccharides from Escherichia coli induced the regression of carcinomatosis and cured 20%-30% of the rats. Some synthetic derivatives of lipid A, which are less toxic than lipopolysaccharides, were injected 14 days after the tumor cells. They induced the complete regression of peritoneal carcinomatosis consisting of numerous nodules measuring 1-5 mm in 20%-30% of rats. Only compounds with three or more hydroxymyristic acid residues were effective. In vivo effects were correlated with the capacity to induce the production of interleukin 1 and tumor necrosis factor but not with the capacity to induce macrophage-mediated cytolysis. It is therefore possible to synthesize weakly toxic derivatives of lipopolysaccharides retaining their antitumoral property in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860636     DOI: 10.1016/0016-5085(91)90532-p

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  Modulation of human colon tumor-stromal interactions by the endothelin system.

Authors:  G Egidy; L Juillerat-Jeanneret; J F Jeannin; P Korth; F T Bosman; F Pinet
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats.

Authors:  N Onier; S Hilpert; L Arnould; V Saint-Giorgio; J G Davies; J F Jeannin; J F Jeannin
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

3.  Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat.

Authors:  K Thomas; A M Nijenhuis; B H Dontje; T Daemen; G L Scherphof
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

4.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

5.  Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

Authors:  Nicolas Isambert; Pierre Fumoleau; Catherine Paul; Christophe Ferrand; Sylvie Zanetta; Jacques Bauer; Kevin Ragot; Gérard Lizard; Jean-François Jeannin; Marc Bardou
Journal:  BMC Cancer       Date:  2013-04-02       Impact factor: 4.430

Review 6.  Immunopharmacology of lipid A mimetics.

Authors:  William S Bowen; Siva K Gandhapudi; Joseph P Kolb; Thomas C Mitchell
Journal:  Adv Pharmacol       Date:  2013

7.  Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment.

Authors:  Amandine Martin; Cédric Seignez; Cindy Racoeur; Nicolas Isambert; Nesrine Mabrouk; Alessandra Scagliarini; Sylvie Reveneau; Laurent Arnould; Ali Bettaieb; Jean-François Jeannin; Catherine Paul
Journal:  Oncotarget       Date:  2018-06-19

8.  Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages.

Authors:  C L Manthey; N Qureshi; P L Stütz; S N Vogel
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.